menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treatment of OAB and the Managed Care Professional: Balancing the Double-Edged Sword

Are you applying an optimal patient-centered, preference-driven treatment plan to your patients diagnosed with overactive bladder?

Live Broadcast
1.00 available credits
Information
June 20, 2023
06:00 PM - 07:00 PM EDT
ReachMD Healthcare Image
Details
Presenters
Related
Comments
  • Overview

    Tune in to this live broadcast on overactive bladder! Experts David Staskin, MD, and Roger Dmochowski, MD, discuss evidence-based best practices in the management and treatment of OAB and integrate challenging case studies throughout the broadcast.

  • Program Schedule*

    Coming Soon!

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Roger Dmochowski, MD
    Professor of Urology, Surgery, and Gynecology
    Vanderbilt University Medical Center
    Nashville, TN 

    Consulting Fees: Urovant Sciences

    David R. Staskin, MD
    Associate Professor, Urology
    Tufts University School of Medicine
    Boston, MA

    Consulting Fees: Astellas Pharma, Inc., Urovant Sciences
    Research: Astellas Pharma, Inc., Urovant Sciences

    Reviewers/Content Planners/Authors:

     

    • Cindy Davidson has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify strategies for screening patients who are likely to have overactive bladder (OAB)
    • Discuss tactics for communicating with older patients about symptoms of OAB
    • Compare the risks and benefits of treatment options for OAB
    • Incorporate patient preferences into the treatment of OAB
  • Target Audience

    This activity is designed to meet the educational needs of primary care providers and managed care pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/.1 CEUs of pharmacy contact hours.1

    The Universal Activity Number for this program is JA0006235-0000-23-020-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Urovant Sciences Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Details
Presenters
Related
Comments
Recommended
  • Overview

    Tune in to this live broadcast on overactive bladder! Experts David Staskin, MD, and Roger Dmochowski, MD, discuss evidence-based best practices in the management and treatment of OAB and integrate challenging case studies throughout the broadcast.

  • Program Schedule*

    Coming Soon!

    *Subject to change

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    Roger Dmochowski, MD
    Professor of Urology, Surgery, and Gynecology
    Vanderbilt University Medical Center
    Nashville, TN 

    Consulting Fees: Urovant Sciences

    David R. Staskin, MD
    Associate Professor, Urology
    Tufts University School of Medicine
    Boston, MA

    Consulting Fees: Astellas Pharma, Inc., Urovant Sciences
    Research: Astellas Pharma, Inc., Urovant Sciences

    Reviewers/Content Planners/Authors:

     

    • Cindy Davidson has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Andrea Mathis has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Colleen Resnick has nothing to disclose. 
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Identify strategies for screening patients who are likely to have overactive bladder (OAB)
    • Discuss tactics for communicating with older patients about symptoms of OAB
    • Compare the risks and benefits of treatment options for OAB
    • Incorporate patient preferences into the treatment of OAB
  • Target Audience

    This activity is designed to meet the educational needs of primary care providers and managed care pharmacists.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour/.1 CEUs of pharmacy contact hours.1

    The Universal Activity Number for this program is JA0006235-0000-23-020-L01-P. This learning activity is live. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Urovant Sciences Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Schedule28 Mar 2024